Provider of serialisation and track-and-trace software solutions, Adents, is advocating pharma manufacturers take advantage of the Drug Supply Chain Security Act’s (DSCSA) one-year enforcement postponement.
Delay
Recently, news broke that penalties for DSCSA infringements will not be enforced until November 2018, even though the law itself will remain unchanged. “With the postponement, companies who have not yet completed the serialisation process stand to gain the most,” said Christophe Devins, CEO of Adents. “As awareness grows of the complexity and interconnectivity of the serialisation process, pharma manufacturers are realising the importance of modularity and flexibility in the solutions they choose.”
According to Adents, the delay in the enforcement date provides valuable time for pharmaceutical manufacturers to look beyond the short-term compliance needs and consider long-term solution viability.
Adents serialised cartons
The company, which offers a serialisation and aggregation suite of software for traceability and documentation compliance, believes this delay will afford manufacturers the time to rethink the overall process, such as incorporating tools that can better meet the track and trace requirements of the DSCSA law.
“In light of the enforcement postponement, we’re looking to educate customers on the versatility and scalability of Adents serialisation solutions,” continued Devins. “The beauty of our software suite is the way it enables companies to comply with short-term serialisation mandates while remaining adaptable for future regulations. Above and beyond that, our solutions allow them to derive additional business value from the tremendous amount of data that gets generated for serialisation purposes.”
